ArticleTranslational cancer research2026
Development and validation of a nomogram for predicting chemotherapy-induced liver injury in breast cancer patients.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy‑induced liver injury (CILI) is a common complication in breast cancer patients, which may lead to treatment interruption and poor prognosis. An effective tool for individualized risk prediction is lacking. This study aimed to develop and validate a nomogram for predicting CILI risk in breast cancer patients undergoing chemotherapy. Methods: A retrospective cohort of breast cancer patients receiving chemotherapy between May 2022 and May 2025 in The Third Affiliated Hospital of Wenzhou Medical University was enrolled. Demographic, clinical, tumor‑related, treatment, and laboratory data were collected. An increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding the normal upper limit is defined as liver dysfunction. Logistic regression with least absolute shrinkage and selection operator (LASSO) variable selection was used to identify independent predictors. A nomogram was constructed. Model performance was assessed by the concordance index (C‑index), calibration curve, decision curve analysis (DCA), and clinical impact curve (CIC). Internal validation was performed using 1,000‑bootstrap resampling. Results: A total of 422 patients were included. Age and chemotherapy regimen (neoadjuvant Conclusions: The proposed nomogram provides an individualized, visual tool for predicting CILI risk in breast cancer patients undergoing chemotherapy. It may assist clinicians in early identification of high‑risk patients, optimizing chemotherapy regimens, and implementing timely liver function protective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.